This independent educational presentation was developed from the TouchTALK KOL Interview with Dr Tedeschi (ASPEN investigator), and covers the latest findings in second-generation BTK inhibitors for patients with WM.
Dr Tedeschi addresses three main topics about the use of BTK inhibitors in WM treatment, and provides data from the phase 3 ASPEN study and differentiation from Ibrutinib and Acalabrutinib. The main topics are as follows:
1. Second-generation BTK inhibitors for patients with WM: What is the potential for improving outcomes?
2. Maximizing outcomes for patients with WM: Adverse events associated with second-generation BTK inhibitors
3. Using BTK inhibitors in clinical practice: How is the landscape changing?
This TouchTALK presentation is an independent educational program developed by TouchOncology, supported by a BeiGene educational grant.